And a one-year study concluded that the drug “dustarlimab,” used to treat endometrial cancer in women, helped cure 18 colorectal cancer patients who participated in this clinical trial.
Commenting on this medical discovery, Dr. Luis Diaz, a member of the US National Cancer Advisory Council, and lead author of the study said the trial is “an important step in the fight against cancer. We will do more research to find out the drug’s effect on other forms of cancer.” cancers such as stomach, prostate and pancreas,” according to the British newspaper “Daily Mail”.
According to the researchers, “dostarlimab” can be used in patients who have tumors with a specific genetic makeup known as microsatellite instability, or MSI.
The drug’s monoclonal antibody works by binding to a protein called PD-1 on the surface of cancer cells, allowing the immune system to destroy cancer cells effectively.
In the study, published in the New England Journal of Medicine, the researchers emphasized that: “At the time of writing this report, no patients had received chemotherapy or radiotherapy or had surgery, and no cases of cancer development or recurrence were reported. reported during follow-up. -up.”
Presenting the findings at the annual meeting of the American Society of Clinical Oncology, study co-author Andrea Sloan Kettering Cancer Center said she was pleased with the team’s findings. It may improve fertility, organ function and sexual health. as well as side effects such as rash, fatigue and nausea.
Despite the promising results of the “miracle” drug, the researchers emphasized the need to conduct more research on a larger number of people, monitor the length of time the drug should be taken, and evaluate the experiment’s few side effects.
It’s worth noting that about 43,000 Britons and 150,000 Americans are diagnosed with colorectal cancer each year, and they kill 17,000 and 53,000 each year in both the UK and America.